

FRAXA Grant/Fellowship Contract

INTRODUCTION

FRAXA Research Foundation, Inc., a Massachusetts nonprofit corporation with a principal place of business at 10 Prince Place, Suite 203, Newburyport, MA 01950 (“FRAXA”) offers a grants and fellowships program designed to encourage research aimed at finding a specific treatment for fragile X syndrome. FRAXA's goal is to bring practical treatment into current medical practice as quickly as possible; therefore, preference will be given to research projects that have a clear practical application and the results of which will be shared with other qualified researchers in a timely fashion.

- **FRAXA Clinical Trial Grants** are flexible in amount and duration. They must involve human subjects with fragile X syndrome. Highest priority is given to clinical trials of potentially disease-modifying therapeutics which have been validated in fragile X animal models.
- **FRAXA Fellowships** of \$50,000 per year for up to 2 years are offered to support individuals to pursue research on fragile X.

AWARD STRUCTURE AND ACCEPTABLE COSTS

Fellowships and grants are funded for one year (unless explicitly authorized for another term) and may be renewed for a second year based on satisfactory progress. Renewal applications are due 60 days before the start date of the additional year of funding.

Fellowships allow for a flexible use of funding; salary support for any personnel with graduate-level experience is permitted. Supply budgets are also allowed.

These limitations do not apply to Clinical Trial Grants. FRAXA reserves the right to cover any item if explicitly authorized by FRAXA's Board of Directors. However, FRAXA is unable to pay for indirect costs under any circumstances for either type of award.

If a project is not initiated within nine months of the date the award is made, the award must be reauthorized by FRAXA's Board of Directors.

REPORTING OBLIGATIONS OF THE GRANTEE

In accepting a grant, the applying institution undertakes that it will:

- Submit within 90 days following the end of the award period to FRAXA a complete final scientific report on the work pursued. On awards of more than one year duration, a yearly scientific report is required.
- Supply an annual accounting of funds received from FRAXA and expenditures made in such detail and in such manner as may meet Internal Revenue Service procedures.

FRAXA Grant/Fellowship Contract

AMENDMENT OF POLICIES

FRAXA Research Foundation reserves the right to modify its policies governing grants at any time and shall provide Grantee Institution with written notice of any changes to such policies that affect the terms of this Agreement. The Grantee agrees to abide by any changes or to terminate the grant within 30 days of the time when such notice is received. Failure to abide by the policies governing grants shall be considered sufficient grounds for cancellation of a grant or refusal to consider any pending application by the grantee.

HUMAN AND ANIMAL SUBJECTS

Human subjects studied in the course of research conducted under a grant are under no circumstances a responsibility of FRAXA. Human subjects in a program supported by FRAXA shall be volunteers in any survey, study or procedure. Research involving human subjects must have Institutional Review Board approval. Research involving animal subjects must have Institutional Animal Care and Use Committee approval.

PUBLICATION AND DISSEMINATION OF RESULTS

FRAXA's purpose in providing grants is to accelerate progress towards treatment for fragile X. Therefore, in accepting an award, the Principal Investigator undertakes to:

- Publish the results of the work pursued in the primary literature in a timely fashion. Once published, the reagents, methods, materials, and products of the work must be made available to other qualified researchers upon reasonable request, subject to Grantee's material transfer agreement as applicable.
- Recognize the support of FRAXA in any published article resulting from the work pursued with a credit line reading "Supported by a grant from FRAXA Research Foundation."
- Recognize the support of FRAXA in any presentation of the work at professional meetings and conferences.

INTELLECTUAL PROPERTY

"Invention" means all discoveries, improvements, and inventions arising from this grant together with all related data, results, and information. Title to any Invention shall reside with the grantee institution. The grantee institution will notify FRAXA promptly after identifying any Invention that the grantee institution believes is patentable and will supply FRAXA, in confidence, with copies of that Invention. Grantee institution shall make reasonable efforts to license the Invention for commercial development to a third-party. For a patented Invention conceived and reduced to

FRAXA Grant/Fellowship Contract

practice that is subsequently licensed under this grant, FRAXA and the grantee institution will negotiate in good faith to enter into a royalty sharing agreement consistent with the grantee institution's policies and procedures solely for the equitable distribution of net income from the Invention, taking into consideration the level of funding provided.

FRAXA Grant/Fellowship Contract

SIGNATURE PAGE

Project Title:

Requested Start Date:

We accept the conditions specified above. We acknowledge and accept the provision that results of this research must be shared with other qualified researchers in a timely fashion.

Signature - Principal Investigator

PI name - please print

Date

Signature - Manager
Office of Grants & Contracts

Name - please print Title

Date

Office of Grants & Contracts Address, Contact Name, Phone, Email:

Institution Tax ID:

Award should be made payable to:

and mailed to: